Annette B. Vogel

Mainz, RP, Germany

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 21 publications

mRNA-based tuberculosis vaccines BNT164a1 and BNT164b1 are immunogenic, well tolerated and efficacious in rodent models.

mRNA-based tuberculosis vaccines BNT164a1 and BNT164b1 are immunogenic, well tolerated and efficacious in rodent models.

Journal: Nature immunology
Published: October 01, 2025

Strong and early immune responses against SARS-CoV-2 in mice and rhesus macaques after BNT162b3 vaccination.

Strong and early immune responses against SARS-CoV-2 in mice and rhesus macaques after BNT162b3 vaccination.

Journal: NPJ vaccines
Published: July 08, 2025

Preclinical characterization of the Omicron XBB.1.5-adapted BNT162b2 COVID-19 vaccine.

Preclinical characterization of the Omicron XBB.1.5-adapted BNT162b2 COVID-19 vaccine.

Journal: NPJ vaccines
Published: May 06, 2024

MEK-inhibitor treatment reduces the induction of regulatory T cells in mice after influenza A virus infection.

MEK-inhibitor treatment reduces the induction of regulatory T cells in mice after influenza A virus infection.

Journal: Frontiers in immunology
Published: December 23, 2023

Reducing cell intrinsic immunity to mRNA vaccine alters adaptive immune responses in mice.

Reducing cell intrinsic immunity to mRNA vaccine alters adaptive immune responses in mice.

Journal: Molecular therapy. Nucleic acids
Published: October 25, 2023

A multivalent mRNA monkeypox virus vaccine (BNT166) protects mice and macaques from orthopoxvirus disease.

A multivalent mRNA monkeypox virus vaccine (BNT166) protects mice and macaques from orthopoxvirus disease.

Journal: Cell
Published: October 04, 2023

The T-cell-directed vaccine BNT162b4 encoding conserved non-spike antigens protects animals from severe SARS-CoV-2 infection.

The T-cell-directed vaccine BNT162b4 encoding conserved non-spike antigens protects animals from severe SARS-CoV-2 infection.

Journal: Cell
Published: January 16, 2023

Toxicological Assessments of a Pandemic COVID-19 Vaccine-Demonstrating the Suitability of a Platform Approach for mRNA Vaccines.

Toxicological Assessments of a Pandemic COVID-19 Vaccine-Demonstrating the Suitability of a Platform Approach for mRNA Vaccines.

Journal: Vaccines
Published: December 30, 2022

Exposure to BA.4/5 S protein drives neutralization of Omicron BA.1, BA.2, BA.2.12.1, and BA.4/5 in vaccine-experienced humans and mice.

Exposure to BA.4/5 S protein drives neutralization of Omicron BA.1, BA.2, BA.2.12.1, and BA.4/5 in vaccine-experienced humans and mice.

Journal: Science immunology
Published: November 15, 2022

mRNA vaccines expressing homo-prototype/Omicron and hetero-chimeric RBD-dimers against SARS-CoV-2.

mRNA vaccines expressing homo-prototype/Omicron and hetero-chimeric RBD-dimers against SARS-CoV-2.

Journal: Cell research
Published: May 12, 2022

BNT162b2 Vaccine Encoding the SARS-CoV-2 P2 S Protects Transgenic hACE2 Mice against COVID-19.

BNT162b2 Vaccine Encoding the SARS-CoV-2 P2 S Protects Transgenic hACE2 Mice against COVID-19.

Journal: Vaccines
Published: March 05, 2021

BNT162b vaccines protect rhesus macaques from SARS-CoV-2.

BNT162b vaccines protect rhesus macaques from SARS-CoV-2.

Journal: Nature
Published: September 01, 2020
Showing 1-12 of 21

Last Updated: 09/26/2026